Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519261-21-00

Acronym

ISG-TULIPS

Enrollment

Registered

2025-09-30

Start date

2025-11-21

Completion date

Unknown

Last updated

2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Desmoplastic small round cell tumor

Brief summary

Overall tumour Response Rate (ORR), according to RECIST v 1.1

Detailed description

Overall Survival (OS), Progression Free Survival (PFS), Duration of Response (DoR), Safety (according to CTC-AE v.5), EORTC-QLQ-C30 and brief inventory pain

Interventions

DRUGIrinotecán Accord 20 mg/ml concentrado para solución para perfusión EFG

DRUGlurbinectedin

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall tumour Response Rate (ORR), according to RECIST v 1.1	—

Secondary

Measure	Time frame
Overall Survival (OS), Progression Free Survival (PFS), Duration of Response (DoR), Safety (according to CTC-AE v.5), EORTC-QLQ-C30 and brief inventory pain	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026